SAFC is investing in the expansion of its manufacturing sites to support biopharmaceutical cell culture production in Lenexa, KS, St. Louis, MO, and Irvine Scotland - creating new Centers of Excellence. This is a $17.3 M program aimed at optimizing its global manufacturing footprint in the US and Europe.
The Lenexa site will be enhanced as the US Center of Excellence for dry powder medium manufacturing. This $6.25 M program, supported by a $250,000 grant from the Kansas Bioscience Authority, will include explanded pin milling and blending capability. The expansion will increase batch capacity by 30% and is slated to be complete by the end of 2010. It will also result in completely separate Animal Component Containing (ACC) and Animal Component Free (ACF) manufacturing spaces. Powder scale up will be seamless from 25 to 4000 Kg in pin milling technology.
Similarly, the St. Louis, MO and the Irvine, Scotland facilities will be augmented as the liquid media, feeds and reagents Centers of Excellence. The improvments will result in an additional ACF manufacturing space in Irvine, and both ACC and ACF dedicated spaces in the St. Louis Broadway facility. Batch capacities will range from 1L to 10,000L at both sites. These are also slated to have construction completed by the end of 2010 with qualification extending into the 1st Qtr of 2011.
"As the biopharm market continues to mature and place an increasing emphasis on efficiency, cost containment and increased regulatory compliance, SAFC will continue its strategy to invest in manufacturing capabilities and facilities that uniquely address these requirments," said SAFC President Gilles Cottier.
Posted by Bruce Lehr July 4th 2010.